FDA panel votes against Capricor's Duchenne heart disease therapy - Reuters
FDA panel votes against Capricor's Duchenne heart disease therapy Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxOak9HZVhUZnY3QmJXSGtDZ0JCdlZ5Q3dWLU9ZYzAyV2pEWFBkREI2aTU5ZnliYkFJay1HNElhbWltSlZBNUtqMFVqMi0wMkdwU0tKQlRYS3NKRDEtd2xXTGFDRkxvaHVYWHFuMFlmVS0zRGNZRXlZRzNOM3llc2NudmNBTFRkcFhNblVxZldJQjNwaUVqLTdESE82WFkyMUJFZzltVENWUlpVcEhOZ0NjaXB1dWFjeWpPUml5YnVRSzROUTFOcVBzTnpBWU5HVEJkbGc?oc=5" target="_blank">FDA panel votes against Capricor's Duchenne heart disease therapy</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
Capricor shares skyrocket as FDA agrees to review new Duchenne drug data - Reuters
Capricor shares skyrocket as FDA agrees to review new Duchenne drug data Reuters
August 14, 2026 at 10:41 AMUS FDA approves Regeneron's rare bone disorder drug - Reuters
US FDA approves Regeneron's rare bone disorder drug Reuters
August 19, 2026 at 06:53 PMNovartis defeats UK court bid to invalidate blockbuster drug Entresto patent - Reuters
Novartis defeats UK court bid to invalidate blockbuster drug Entresto patent Reuters
August 13, 2026 at 09:31 PMUS FDA approves Bristol Myers' blood cancer treatment - Reuters
US FDA approves Bristol Myers' blood cancer treatment Reuters
August 13, 2026 at 09:33 PMEyePoint's drug for age-related eye disease fails late-stage trial, shares tank - Reuters
EyePoint's drug for age-related eye disease fails late-stage trial, shares tank Reuters
August 17, 2026 at 03:45 PMPrader-Willi experts flag safety risks linked to Neurocrine's rare disease drug - Reuters
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug Reuters
August 12, 2026 at 04:25 PM